BCM
ALLO icon

Bayesian Capital Management’s Allogene Therapeutics ALLO Stock Holding History

Bayesian Capital Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,402
Closed -$82.5K – 655
2024
Q2 		$82.5K Buy
+35,402
New +$104K 0.01% 657
2023
Q4 		– Sell
-26,500
Closed -$84K – 725
2023
Q3 		$84K Buy
26,500
+12,400
+88% +$54.3K 0.01% 620
2023
Q2 		$70.1K Buy
+14,100
New +$76.3K 0.01% 712
2022
Q2 		– Sell
-30,400
Closed -$277K – 763
2022
Q1 		$277K Buy
+30,400
New +$317K 0.04% 544

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bayesian Capital Management's ALLO Position: Q3 2024 in Review

Bayesian Capital Management sold out of Allogene Therapeutics (ALLO) in Q3 2024, closing a stake of 35,402 shares — an estimated $82.5K sold.

Bayesian Capital Management first reported a position in ALLO in Q1 2022 and held it in 4 quarters. The position peaked at $277K in Q1 2022. 156 funds tracked by Wall St. Rank hold ALLO as of Q3 2024.

  • Bayesian Capital Management reported no remaining Allogene Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Bayesian Capital Management sold 35,402 Allogene Therapeutics shares in Q3 2024, an estimated $82.5K.
  • Bayesian Capital Management first reported a position in Allogene Therapeutics in Q1 2022 and held it in 4 quarters.
  • Bayesian Capital Management's Allogene Therapeutics position peaked at $277K in Q1 2022.
  • 156 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2024.

Based on Bayesian Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.